We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Evaluate Recovery of Testosterone for Patients Using Eligard (Eligard)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 3, 2010
Last Update Posted: July 22, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Chesapeake Urology Research Associates
The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.

Condition Intervention Phase
Prostate Cancer Drug: Eligard (TM) Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Chesapeake Urology Research Associates:

Primary Outcome Measures:
  • Serum Testosterone Recovery [ Time Frame: 6 mos ]
    To Evaluate the time to testosterone recovery, which is defined as a return to with in 90% of pretreatment level, after 6 months of neo-adjuvant treatment with Eligard 22.5mg with Radiation Therapy in patients with early prostate Cancer

Secondary Outcome Measures:
  • Safety Assessments [ Time Frame: 6 months ]
    Assess frequency and severity of spontaneously reported AE's Changes between baseline and testosterone recovery in serum testosterone and pre biopsy PSA clinical evidence of Prostate cancer changes between baseline and testosterone recovery in health questionnaire

Enrollment: 42
Study Start Date: October 2003
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Single Arm- Eligard
Eligard 22.5mg is only intervention administered
Drug: Eligard (TM)
22.5 mg administered at baseline and Month 3


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must be outpatient, not hospitalized
  • Male Patient between ages 50-80, inclusive
  • Histologically/Cytologically graded adenocarcinoma of the prostate
  • Must have T1, T2 or T3a adenocarcinoma of the prostate
  • Must be a candidate for radiation therapy. Hormone refractory patients excluded
  • WHO/ECOG score of 0,1 or 2

Exclusion Criteria:

  • NO evidence of urinary tract that would put the patient at risk in the opinion of the Investigator.
  • Used the following treatments for prostate Cancer

    *immunotherapy *chemotherapy *External Beam Radiation *brachytherapy *hormonal therapy *biological response modifiers

  • Prior Prostate Surgery (excluding TUNA or TURP)
  • Undergone Orchiectomy, adrenalectomy, hypophysectomy or be receiving any product which could alter the function of these organs
  • Use of Investigational Drug, Biologic or device within five half-lives of its physiological action or three months prior to base line, whichever is longer
  • Over the counter or alternative medical therapies which have estrogenic or anti-androgenic effect
  • uncontrolled CHF within 6 months to baseline
  • Myocardial Infarct, coronary vascular procedure or Clinically SignificantCardiovascualr Disease within 6 months of baseline Visit
  • Venous thrombosis with in 6 Months of Screening
  • Uncontrolled Hypertension defined as >170/100 or Symptomatic Hypotension within 3 months of Baseline
  • Insulin dependant Diabetic Patients Must not administer in an anatomic region where they will receive Eligard.
  • Drug or Alcohol Abuse 6 months prior to Baseline
  • Other Serious Illness at the discretion of the Investigator
  • Patients receiving anti-coagulant or anti-platlet medication must be on a stable dose for 3 months prior to Baseline
  • Hypersensitivity to GnRH, GnRH agonists
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Chesapeake Urology Research Associates
ClinicalTrials.gov Identifier: NCT01136226     History of Changes
Other Study ID Numbers: CURA-RT-001
First Submitted: June 2, 2010
First Posted: June 3, 2010
Results First Submitted: April 12, 2013
Results First Posted: July 16, 2013
Last Update Posted: July 22, 2013
Last Verified: July 2013

Keywords provided by Chesapeake Urology Research Associates:
Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents